- Home
- ONEG vs LGVN Comparison
ONEG vs LGVN Comparison
Compare ONEG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | LGVN |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Hong Kong | United States |
| Employees | 26 | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 34.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ONEG | LGVN |
|---|---|---|
| Price | $3.59 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 574.0K | ★ 2.0M |
| Earning Date | 01-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.48 |
| 52 Week High | $13.50 | $1.83 |
Technical Indicators
Market Signals| Indicator | ONEG | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 74.14 | 60.28 |
| Support Level | $1.16 | $0.69 |
| Resistance Level | $5.70 | $1.23 |
| Average True Range (ATR) | 0.43 | 0.10 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 92.31 | 67.51 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.